1. Home
  2. BNZI vs APVO Comparison

BNZI vs APVO Comparison

Compare BNZI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banzai International Inc.

BNZI

Banzai International Inc.

HOLD

Current Price

$1.01

Market Cap

9.6M

Sector

N/A

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$0.61

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNZI
APVO
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
21.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNZI
APVO
Price
$1.01
$0.61
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
395.5K
1.8M
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,650,176.00
N/A
Revenue This Year
$205.97
N/A
Revenue Next Year
$31.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.06
N/A
52 Week Low
$0.94
$0.50
52 Week High
$27.00
$109.80

Technical Indicators

Market Signals
Indicator
BNZI
APVO
Relative Strength Index (RSI) 35.09 21.84
Support Level $0.94 $1.00
Resistance Level $1.08 $1.11
Average True Range (ATR) 0.10 0.10
MACD 0.02 -0.04
Stochastic Oscillator 15.48 10.67

Price Performance

Historical Comparison
BNZI
APVO

About BNZI Banzai International Inc.

Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: